Eli Lilly Gets Green Light For New Use Of Gemzar

Law360, New York (July 17, 2006, 12:00 AM EDT) -- The U.S. Food and Drug Administration has given Eli Lilly & Co. the go-ahead to use its drug Gemzar to treat women with recurrent ovarian cancer.

Gemzar, gemcitabine HCl, has received FDA approval for the treatment of non-small cell lung cancer and metastatic breast cancer since its initial approved in 1996 for the treatment of advanced pancreatic cancer.

"Ovarian cancer is marked by one of the highest recurrence rates of all women's cancers, and when it does progress, it is frequently accompanied by significant symptoms that...
To view the full article, register now.